TCP
PTLA

Tourbillon Capital Partners’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

Tourbillon Capital Partners’s Portfolio PTLA Stock Details PTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-139,400
Closed -$7.83M – 80
2017
Q2 		$7.83M Buy
139,400
+35,600
+34% +$1.43M 0.15% 67
2017
Q1 		$4.07M Buy
+103,800
New +$3.31M 0.1% 55

Other funds holding PTLA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CCM
Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Tourbillon Capital Partners's PTLA Position: Q3 2017 in Review

Tourbillon Capital Partners sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q3 2017, closing a stake of 198,903 shares — an estimated $11.2M sold.

Tourbillon Capital Partners first reported a position in PTLA in Q1 2015 and held it in 6 quarters. The position peaked at $34.2M in Q4 2015. 221 funds tracked by Wall St. Rank hold PTLA as of Q3 2017.

  • Tourbillon Capital Partners reported no remaining Portola Pharmaceuticals, Inc. position as of Q3 2017 after selling out during the quarter.
  • Tourbillon Capital Partners sold 198,903 Portola Pharmaceuticals, Inc. shares in Q3 2017, an estimated $11.2M.
  • Tourbillon Capital Partners first reported a position in Portola Pharmaceuticals, Inc. in Q1 2015 and held it in 6 quarters.
  • Tourbillon Capital Partners's Portola Pharmaceuticals, Inc. position peaked at $34.2M in Q4 2015.
  • 221 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q3 2017.

Based on Tourbillon Capital Partners's 13F filing for Q3 2017, filed 14 Nov 2017.